CN111212648B - 用于预防或治疗肌肉疾患的组合物和方法 - Google Patents

用于预防或治疗肌肉疾患的组合物和方法 Download PDF

Info

Publication number
CN111212648B
CN111212648B CN201880050726.2A CN201880050726A CN111212648B CN 111212648 B CN111212648 B CN 111212648B CN 201880050726 A CN201880050726 A CN 201880050726A CN 111212648 B CN111212648 B CN 111212648B
Authority
CN
China
Prior art keywords
muscle
pge2
cases
toxin
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201880050726.2A
Other languages
English (en)
Chinese (zh)
Other versions
CN111212648A (zh
Inventor
哈维·菲什曼
凯瑟琳·柯廷
克里斯托弗·佩恩
斯科特·德尔普
威威克·沙诺伊
海伦·M·布劳
安得烈·崔范何
阿德莱达·R·帕拉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Meovo Therapy
Leland Stanford Junior University
Original Assignee
Meovo Therapy
Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Meovo Therapy, Leland Stanford Junior University filed Critical Meovo Therapy
Publication of CN111212648A publication Critical patent/CN111212648A/zh
Application granted granted Critical
Publication of CN111212648B publication Critical patent/CN111212648B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A61K31/245—Amino benzoic acid types, e.g. procaine, novocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/32—Manganese; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/58—Reptiles
    • A61K35/583—Snakes; Lizards, e.g. chameleons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/63—Arthropods
    • A61K35/64—Insects, e.g. bees, wasps or fleas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Insects & Arthropods (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Animal Husbandry (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
CN201880050726.2A 2017-06-09 2018-06-08 用于预防或治疗肌肉疾患的组合物和方法 Active CN111212648B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762517758P 2017-06-09 2017-06-09
US62/517,758 2017-06-09
PCT/US2018/036727 WO2018227134A1 (en) 2017-06-09 2018-06-08 Compositions and methods for preventing or treating muscle conditions

Publications (2)

Publication Number Publication Date
CN111212648A CN111212648A (zh) 2020-05-29
CN111212648B true CN111212648B (zh) 2024-07-09

Family

ID=64566381

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880050726.2A Active CN111212648B (zh) 2017-06-09 2018-06-08 用于预防或治疗肌肉疾患的组合物和方法

Country Status (9)

Country Link
US (4) US20190167695A1 (enExample)
EP (1) EP3634424A4 (enExample)
JP (2) JP7372911B2 (enExample)
KR (1) KR102698911B1 (enExample)
CN (1) CN111212648B (enExample)
AU (1) AU2018280264B2 (enExample)
CA (1) CA3065945A1 (enExample)
GB (1) GB2578539B (enExample)
WO (2) WO2018227134A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4538365A3 (en) 2016-03-04 2025-07-30 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for muscle regeneration using prostaglandin e2
EP3548035A4 (en) 2016-11-30 2020-07-22 Case Western Reserve University COMBINATIONS OF 15-PGDH INHIBITORS WITH CORCOSTEROIDS AND / OR TNF INHIBITORS AND THEIR USES
CN110573154A (zh) 2017-02-06 2019-12-13 卡斯西部储备大学 调节短链脱氢酶活性的组合物和方法
GB2578539B (en) 2017-06-09 2022-08-10 Univ Leland Stanford Junior Compositions and methods for preventing or treating muscle conditions
WO2020106998A1 (en) 2018-11-21 2020-05-28 Case Western Reserve University Compositions and methods of modulating short-chain dehydrogenase activity
GB2599292A (en) * 2019-06-11 2022-03-30 Univ Leland Stanford Junior Methods of rejuvenating aged tissue by inhibiting 15-hydroxyprostaglandin dehydrogenase (15-PGDH)
WO2021011747A1 (en) * 2019-07-16 2021-01-21 Children’S National Medical Center Method for treatment of muscular dystrophy
JP7677983B2 (ja) 2020-01-23 2025-05-15 マイオフォルテ セラピューティクス，インク． Ｐｇｄｈ阻害剤、およびその作製と使用の方法
AU2021224268A1 (en) 2020-02-21 2022-09-15 Case Western Reserve University Compositions and methods for treating renal injury
US20230187041A1 (en) * 2020-05-08 2023-06-15 Intime Biotech Llc Real-time method of bio big data automatic collection for personalized lifespan prediction
EP4228650A4 (en) * 2020-10-15 2024-12-18 Myoforte Therapeutics Inc. INHALATED FORMULATIONS OF PGDH INHIBITORS AND METHODS OF USE THEREOF
CN117377668A (zh) * 2020-10-15 2024-01-09 迈欧伏特治疗公司 Pgdh抑制剂的吸入制剂及其使用方法
US20240000758A1 (en) * 2020-10-23 2024-01-04 The Board Of Trustees Of The Leland Stanford Junior University Elevation of mitochondrial biogenesis and function by inhibition of prostaglandin degrading enzyme 15-pgdh
JP7501333B2 (ja) * 2020-12-07 2024-06-18 コニカミノルタ株式会社 超音波診断装置、超音波診断装置の制御方法、及び、超音波診断装置の制御プログラム
JP2023552832A (ja) * 2020-12-09 2023-12-19 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 関節の構造および機能を改善するためのプロスタグランジン分解酵素１５－ｐｇｄｈの阻害法
CN113327235B (zh) * 2021-06-04 2022-07-01 杭州健培科技有限公司 基于ct影像肌少症评估的图像处理方法和装置
CN114107272B (zh) * 2021-12-15 2022-06-24 徐州医科大学 mPGES-2作为靶点在开发或筛选或制备用于预防和/或治疗衰老疾病的药物中的应用
US12558549B2 (en) 2022-10-28 2026-02-24 Medtronic, Inc. Lead based measurements for tongue movement determination
CN117142939B (zh) * 2023-10-30 2024-01-16 成都中医药大学 一种倍半萜化合物及其制备方法和用途及其制备的药物
CN117473328B (zh) * 2023-12-26 2024-03-15 南京麦豆健康科技有限公司 一种基于大数据的阴道松弛评估训练系统及方法
CN118351102B (zh) * 2024-05-06 2024-11-19 上海交通大学医学院附属瑞金医院 基于脑白质磁共振信号强度的图像处理方法和系统
CN119331890B (zh) * 2024-12-24 2025-03-07 中国农业科学院蜜蜂研究所 基因15-pgdh在调控蜜蜂工蜂体重、体长中的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5962528A (en) * 1991-07-03 1999-10-05 Scott; Nathan Earl Prostaglandin E2 /F2α combination for treating impotence
US7632848B1 (en) * 2007-10-04 2009-12-15 Alan Brown Scott Medical treatment of muscles by exposure to anesthetic drugs

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3927213A (en) 1973-07-10 1975-12-16 American Home Prod Prostaglandin E{HD 2 {B and derivatives for reducing the side effects of anti-inflammatory agents
US5143842A (en) 1988-11-01 1992-09-01 The University Of Colorado Foundation, Inc. Media for normal human muscle satellite cells
WO1991012329A2 (en) 1990-02-12 1991-08-22 Board Of Regents, The University Of Texas System Satellite cell proliferation in adult skeletal muscle
US5409911A (en) 1992-09-11 1995-04-25 Merck & Co., Inc. Prostaglandin analog for treating osteoporosis
US5736396A (en) 1995-01-24 1998-04-07 Case Western Reserve University Lineage-directed induction of human mesenchymal stem cell differentiation
US5833978A (en) 1995-03-16 1998-11-10 Universite Laval Method of in vitro preconditioning healthy donor's myoblasts before transplantation thereof in compatible patients suffering of recessive myopathies like muscular dystrophy, for improving transplantation success
US5599561A (en) * 1995-08-04 1997-02-04 Gonzalez, Jr.; Angel Method of making poultice
ATE327751T1 (de) 2000-01-31 2006-06-15 Pfizer Prod Inc Verwendung von aktivatoren des prostaglandinrezeptores 4 zur behandlung von akuter oder chronischer niereninsuffizienz
US6410591B1 (en) 2001-05-08 2002-06-25 Allergan Sales, Inc. 3,7 or 3 and 7 thia or oxa prostanoic acid derivatives as agents for lowering intraocular pressure
JP4273407B2 (ja) 2001-07-23 2009-06-03 小野薬品工業株式会社 Ｅｐ４アゴニストを有効成分とする骨量低下疾患の治療剤
US7772433B2 (en) 2002-02-28 2010-08-10 University Of Tennessee Research Foundation SARMS and method of use thereof
US20040058313A1 (en) 2002-04-24 2004-03-25 Abreu Marcio Marc Compositions, targets, methods and devices for the therapy of ocular and periocular disorders
HUE029417T2 (en) * 2002-10-10 2017-02-28 Ono Pharmaceutical Co Microspheres containing ONO-1301
US6841573B2 (en) 2002-11-27 2005-01-11 Molecular Nutrition Use of arachidonic acid as a method of increasing skeletal muscle mass
US6747037B1 (en) 2003-06-06 2004-06-08 Allergan, Inc. Piperidinyl prostaglandin E analogs
US7326732B2 (en) 2004-02-12 2008-02-05 Pharmagene Laboratories Limited EP2 receptor agonists
US7169807B2 (en) 2004-04-09 2007-01-30 Allergan, Inc. 10-Hydroxy-11-dihydroprostaglandin analogs as selective EP4 agonists
US7696235B2 (en) 2005-08-29 2010-04-13 Allergan, Inc. EP2 receptor agonists for treating glaucoma
AR059430A1 (es) 2006-02-09 2008-04-09 Schering Corp Novedosas combinaciones y metodos de inhibidores del vhc
EP1999255A2 (en) 2006-03-24 2008-12-10 The Children's Medical Center Corporation Method to modulate hematopoietic stem cell growth
CA2652040C (en) 2006-05-17 2015-07-21 Albert Einstein College Of Medicine Of Yeshiva University Prostaglandin transporter inhibitors
AU2007280130B2 (en) 2006-07-28 2011-09-22 Pfizer Products Inc. EP2 agonists
WO2008157753A1 (en) 2007-06-21 2008-12-24 Sma Foundation Methods of treatment for spinal muscular atrophy
BRPI0819707A2 (pt) 2007-11-29 2015-06-16 Allergan Inc Ciclopentanos substituídas tendo atividade de prostaglandina
US8871752B2 (en) 2008-02-19 2014-10-28 Sucampo Ag Method for modulating stem cell growth
CN102057037B (zh) 2008-04-11 2014-06-18 学校法人庆应义塾 平滑肌干细胞的分离方法
US20110004589A1 (en) 2009-07-06 2011-01-06 Rockwell Automation Technologies, Inc. Diagnostics in a distributed directory system
US8193220B1 (en) 2009-08-20 2012-06-05 Alan Brown Scott Method of changing muscle lengths with anesthetic drugs
EP2637702A4 (en) 2010-11-11 2014-11-26 Univ Miami METHODS, COMPOSITIONS, CELLS AND KITS FOR TREATING ISCHEMIC INJURIES
US9782417B2 (en) 2011-06-16 2017-10-10 Presidents And Fellows Of Harvard College Methods of increasing satellite cell proliferation with kinase inhibitors
WO2012174537A2 (en) 2011-06-16 2012-12-20 President And Fellows Of Harvard College Small molecule screening for mouse satellite cell proliferation
EP2785350B1 (en) 2011-12-02 2018-05-02 Fate Therapeutics, Inc. Improved methods of treating ischemia
CA2870666A1 (en) * 2012-04-16 2013-10-24 Case Western Reserve University Compositions and methods of modulating 15-pgdh activity
KR101244964B1 (ko) 2012-05-30 2013-03-18 조선대학교산학협력단 15-히드록시프로스타글란딘 디히드로게나제 및 ｐｇｅ2 활성을 조절하는 황칠나무 추출물의 용도
US20130331389A1 (en) 2012-06-11 2013-12-12 National Cheng Kung University Methods and Compositions for Cardiomyocyte Replenishment by Endogenous and Progenitor Stem Cells
US9154479B1 (en) 2012-09-14 2015-10-06 Amazon Technologies, Inc. Secure proxy
CA2927730A1 (en) 2013-10-15 2015-05-07 Case Western Reserve University Compositions and methods of modulating short-chain dehydrogenase activity
CA2974903A1 (en) 2015-01-26 2016-08-04 Fate Therapeutics, Inc. Cells with increased immuno-regulatory properties and methods for their use and manufacture
EP4538365A3 (en) 2016-03-04 2025-07-30 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for muscle regeneration using prostaglandin e2
GB2578539B (en) 2017-06-09 2022-08-10 Univ Leland Stanford Junior Compositions and methods for preventing or treating muscle conditions

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5962528A (en) * 1991-07-03 1999-10-05 Scott; Nathan Earl Prostaglandin E2 /F2α combination for treating impotence
US7632848B1 (en) * 2007-10-04 2009-12-15 Alan Brown Scott Medical treatment of muscles by exposure to anesthetic drugs

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Inhibited Skeletal Muscle Healing in Cyclooxygenase-2 Gene-Deficient Mice: The Role of PGE2 and PGF2α;Wei Shen等;Journal of Applied Physiology;第101卷;1215-1221 *

Also Published As

Publication number Publication date
GB201919382D0 (en) 2020-02-05
CN111212648A (zh) 2020-05-29
EP3634424A1 (en) 2020-04-15
JP7372911B2 (ja) 2023-11-01
GB2578539A (en) 2020-05-13
JP2020523409A (ja) 2020-08-06
US11738031B2 (en) 2023-08-29
US20240115583A1 (en) 2024-04-11
US20260144801A1 (en) 2026-05-28
EP3634424A4 (en) 2021-06-09
US20190167695A1 (en) 2019-06-06
WO2018227134A1 (en) 2018-12-13
JP2023139260A (ja) 2023-10-03
AU2018280264A1 (en) 2020-01-02
KR20200015735A (ko) 2020-02-12
WO2018227138A1 (en) 2018-12-13
KR102698911B1 (ko) 2024-08-23
US20220265677A1 (en) 2022-08-25
CA3065945A1 (en) 2018-12-13
AU2018280264B2 (en) 2024-07-11
GB2578539B (en) 2022-08-10

Similar Documents

Publication Publication Date Title
US11738031B2 (en) Compositions and methods for preventing or treating muscle conditions
AU2022268368B2 (en) Compositions and methods for muscle regeneration using prostaglandin E2
Alvarez et al. Ectopic uterine tissue as a chronic pain generator
JP2005516054A (ja) コネキシンヘミチャンネルを調節する組成物及びその方法
US20200108069A1 (en) Treatment of Fibrotic Conditions
EP3097423B1 (en) Selection of agents modulating gastrointestinal pain
AU2014365665B2 (en) Use of PAR-1 antagonists for preventing and/or treating pelvi-perineal functional pathological conditions
US20160000804A1 (en) Inhibitors of na(v) 1.9 channel activity and uses thereof for treating pain
Parson Targeting the Beiging of Muscle-Associated Adipose Tissue to Promote Muscle Regeneration
BR122025016540A2 (pt) Composição compreendendo um pge2, um derivado de pge2, um análogo de pge2, um pró-fármaco de pge2 ou um agonista do receptor ep4 de prostaglandina, e seu uso

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
TG01 Patent term adjustment

Free format text: NEW EXPIRY DATE: 20380815

TG01 Patent term adjustment